摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-cyano-1-ethoxycarbonyl-2-chloro-2-(trifluoromethyl)ethylene | 77429-04-0

中文名称
——
中文别名
——
英文名称
1-cyano-1-ethoxycarbonyl-2-chloro-2-(trifluoromethyl)ethylene
英文别名
ethyl 3-chloro-2-cyano-4,4,4-trifluorobut-2-enoate;C7H5ClF3NO2
1-cyano-1-ethoxycarbonyl-2-chloro-2-(trifluoromethyl)ethylene化学式
CAS
77429-04-0
化学式
C7H5ClF3NO2
mdl
——
分子量
227.57
InChiKey
QPMJENKZJUFOON-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    50.1
  • 氢给体数:
    0
  • 氢受体数:
    6

安全信息

  • 危险性防范说明:
    P280,P305+P351+P338
  • 危险性描述:
    H317,H319

反应信息

  • 作为反应物:
    描述:
    1-cyano-1-ethoxycarbonyl-2-chloro-2-(trifluoromethyl)ethylene一水合肼三乙胺 作用下, 以 乙醇 为溶剂, 以56.4%的产率得到5-氨基-3-三氟甲基-4-吡唑甲酸乙酯
    参考文献:
    名称:
    三氟甲基促进的功能性吡唑并[1,5- a ]嘧啶和吡唑并[5,1- d ] [1,2,3,5]四嗪-4(3 H)-ones的合成
    摘要:
    通过氰基乙酸乙酯和三氟乙酸酐的缩合,然后氯化和与肼水溶液的缩合,有效地合成了5-氨基-3-三氟甲基-1 H-吡唑-4-羧酸乙酯(1)。其独特的反应活性被用于合成三氟甲基化的吡唑并[1,5- a ]嘧啶(5)和吡唑并[5,1- d ] [1,2,3,5]四嗪-4(3 H)-(8a – j)。其中5首先发现它是一种新颖的荧光分子,可被用作具有许多结合位点的引人注目的荧光团,并且其荧光强度明显强于其甲基类似物。8被发现是新的化学类别的潜在的单子叶稗草L. Beauv抑制剂,和比其甲基类似物更具活性。
    DOI:
    10.1016/j.jfluchem.2006.02.001
  • 作为产物:
    描述:
    sodium 1-trifluoromethyl-2-cyano-2-ethoxycarbonylvinyl oxide 在 phenylphosphorus tetrachloride 作用下, 以59.8%的产率得到1-cyano-1-ethoxycarbonyl-2-chloro-2-(trifluoromethyl)ethylene
    参考文献:
    名称:
    Krokhtyak, V. I.; Il'chenko, A. Ya.; Yagupol'skii, L. M., Journal of Organic Chemistry USSR (English Translation), 1981, p. 219 - 222
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] N-(4-(AZAINDAZOL-6-YL)PHÉNYL)SULFONAMIDES ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
    申请人:SANOFI SA
    公开号:WO2014140065A1
    公开(公告)日:2014-09-18
    N-(4-(Azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals The present invention relates to N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides of the formula I, wherein Ar, n, X, Z, R1, R2 and R3 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.
    本发明涉及公式I的N-(4-(吡唑吲唑-6-基)-苯基)-磺酰胺,其中Ar、n、X、Z、R1、R2和R3具有索引中指示的含义。公式I的化合物是有价值的药理活性化合物,可以调节蛋白激酶活性,特别是血清和糖皮质激素调节激酶(SGK)的活性,特别是血清和糖皮质激素调节激酶同工酶1(SGK-1,SGK1)的活性,并适用于治疗SGK活性不当的疾病,例如退行性关节疾病或炎症过程,如骨关节炎或风湿病。本发明还涉及公式I的化合物的制备方法,它们作为药物的用途,以及包含它们的药物组合物。
  • N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS
    申请人:SANOFI
    公开号:US20160024097A1
    公开(公告)日:2016-01-28
    The present invention relates to N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides of the formula I, wherein Ar, n, X, Z, R1, R2 and R3 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.
    本发明涉及式I中的N-(4-(氮杂吲唑-6-基)-苯基)-磺酰胺,其中Ar、n、X、Z、R1、R2和R3在权利要求中指定了它们的含义。式I化合物是有价值的药理活性化合物,可以调节蛋白激酶活性,特别是血清和糖皮质激素调节激酶(SGK)的活性,特别是血清和糖皮质激素调节激酶亚型1(SGK-1,SGK1)的活性,并适用于治疗SGK活性不当的疾病,例如退行性关节疾病或炎症过程,如骨关节炎或风湿病。此外,本发明还涉及制备式I化合物的方法,它们作为药物的用途以及包含它们的制剂。
  • Shokol, V. A.; Kozhushko, B. N.; Paliichuk, Yu. A., Journal of general chemistry of the USSR, 1990, vol. 60, # 7.2, p. 1487 - 1488
    作者:Shokol, V. A.、Kozhushko, B. N.、Paliichuk, Yu. A.
    DOI:——
    日期:——
  • Il'chenko, A. Ya.; Koval'chuk, R. E.; Krokhtyak, V. I., Journal of Organic Chemistry USSR (English Translation), 1981, vol. 17, p. 2348 - 2349
    作者:Il'chenko, A. Ya.、Koval'chuk, R. E.、Krokhtyak, V. I.、Yagupol'skii, L. M.
    DOI:——
    日期:——
  • Krokhtyak, V. I.; Il'chenko, A. Ya.; Yagupol'skii, L. M., Journal of Organic Chemistry USSR (English Translation), 1981, p. 219 - 222
    作者:Krokhtyak, V. I.、Il'chenko, A. Ya.、Yagupol'skii, L. M.
    DOI:——
    日期:——
查看更多